5 active trials 2 recruiting 1 Phase 3 4 disease areas 1 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Trial sites reduced: 56 → 52 locations
Servier Bio-Innovation LLCPhase 1/2 NCT06162572 Registry history of NCT06162572 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 1 | |
| Phase 1/2 | 3 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional… | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | Recruiting | 2026-02-06 |
| Phase 1/2 | ||||
| NCT06162572 | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With… | Non-small Cell Lung Cancer (NSCLC) | Active, Not Recruiting | 2026-10-09 |
| NCT06188702 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… | MTAP-deleted Solid Tumors | Active, Not Recruiting | 2026-08-25 |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy… | MSI-H/dMMR Gastroesophageal-junction Cancer | Active, Not Recruiting | 2026-04-03 |
| Phase 1 | ||||
| NCT07006688 | A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic… | IDH1-Mutated Malignancies | Recruiting | 2026-08-06 |
Gastric Cancer (1) · Lung Cancer (1) · Non-Small Cell Lung Cancer (NSCLC) (1) · Sarcoma (1)